Many pharmaceutical companies want to see more new therapies entering the market—and delivering positive outcomes to patients. But it can take a decade of research and review and billions of dollars to produce just one drug, an unfathomably large investment that will only grow over time as researchers address more complex diseases.
To accelerate progress without risking runaway costs, global pharmaceutical companies are exploring how quickly evolving capabilities of generative artificial intelligence (AI) can augment internal processes and systems to help researchers speed effective delivery.